Nantahala Capital Management’s Cogent Biosciences COGT Stock Holding History

Nantahala Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.62M	Hold	250,000	–	–	0.35%	72
2025 Q4	$8.88M	Sell	250,000 -1,256,989	-83%	-$35.3M	0.29%	82
2025 Q3	$21.6M	Sell	1,506,989 -148,700	-9%	-$1.76M	0.75%	29
2025 Q2	$11.9M	Buy	1,655,689 +812,200	+96%	+$4.5M	0.47%	46
2025 Q1	$5.05M	Sell	843,489 -9,366	-1%	-$73.4K	0.2%	68
2024 Q4	$6.65M	Buy	852,855 +61,919	+8%	+$617K	0.29%	64
2024 Q3	$8.54M	Hold	790,936	–	–	0.43%	47
2024 Q2	$6.67M	Hold	790,936	–	–	0.39%	53
2024 Q1	$5.32M	Buy	790,936 +150,000	+23%	+$927K	0.3%	58
2023 Q4	$3.77M	Buy	640,936 +65,936	+11%	+$505K	0.23%	73
2023 Q3	$5.61M	Buy	575,000 +510,868	+797%	+$6.06M	0.48%	49
2023 Q2	$759K	Buy	+64,132	New	+$736K	0.07%	98

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Nantahala Capital Management's COGT Position: Q1 2026 in Review

Nantahala Capital Management held its Cogent Biosciences (COGT) position steady in Q1 2026 at 250,000 shares worth $9.62M. The position accounts for 0.35% of the portfolio, ranked #72.

Nantahala Capital Management first reported a position in COGT in Q2 2023 and has held it in 12 quarters since. The position peaked at $21.6M in Q3 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Nantahala Capital Management held 250,000 shares of Cogent Biosciences worth $9.62M as of Q1 2026.
Nantahala Capital Management left its Cogent Biosciences share count unchanged in Q1 2026.
Cogent Biosciences made up 0.35% of Nantahala Capital Management's portfolio in Q1 2026, its #72 holding.
Nantahala Capital Management first reported a position in Cogent Biosciences in Q2 2023 and has held it in 12 quarters since.
Nantahala Capital Management's Cogent Biosciences position peaked at $21.6M in Q3 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.